ClinicalTrials.gg
CompletedNCT05045170Updated Feb 9, 2022

Sedation and Memory Consolidation

An interventional study of Influence of propofol sedation on memory consolidation and 'working memory' and Influence of dexmedetomidine sedation on memory consolidation and 'working memory' in Memory Impairment, Amnesia and Recall, sponsored by I.M. Sechenov First Moscow State Medical University. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-09.

Primary conditionAmnesiaRegistry: Memory DisordersReclassifiedWhy we changed it
Registry
Memory Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Amnesia
Why
  1. The study's listed conditions name Amnesia, a narrower term within Memory Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by I.M. Sechenov First Moscow State Medical University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2021, registered Sep 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The study of plasticity processes, in particular, memory, is one of the fundamental directions in anesthesiology. To date, there are different views on the impact of sedation and anesthesia on memory. Memory consolidation is one of the most crucial processes that the anesthesiologist is interested in. Memory consolidation is the mechanism of transferring short-term memory to long-term memory. The investigators suppose that propofol or dexmedetomidine sedation disrupts memory consolidation. In addition, the investigators inquired about the impact of sedation on 'working memory'. Therefore, a better understanding of the influence of anesthesia and sedation on basic memory processes will allow the anesthesiologist to balance the choice of the drug and ensure the patient's safety in the intraoperative period.

Read the detailed description

The study is a prospective, randomized, single blind design. Patients undergoing elective trauma surgery (arthroscopy, reconstructive foot surgery) under subarachnoidal anesthesia are enrolled in this study. All patients were randomly divided into three groups depending on the drug type: first - propofol, second - dexmedetomidine, third - control.

The Montreal cognitive assessment test (MoCA - test) is a high validity test. MoCA - test is used to determine cognitive impairments in patients in the pre-operative period. The MoCA test time is approximately 10 minutes. The maximum possible score is 30; 26 points and more are considered normal, 25 or less is evidence of cognitive impairment.

American Society of Anesthesiologists (ASA) physical status classification system is used to assess and communicate a patient's pre-anesthesia medical co-morbidities (ASA I - a normal healthy patient, ASA II - a patient with mild systemic disease, ASA III - a patient with severe systemic disease, ASA IV - a patient with severe systemic disease that is a constant threat to life, ASA V - a moribund patient who is not expected to survive without the operation, ASA VI - a declared brain-dead patient whose organs are being removed for donor purposes.

To determine the level of anxiety and depression in the preoperative period, patients are tested using the Hospital Anxiety and Depression Scale (HADS). Values on the HADS scale\<7 points are interpreted as normal, with scores from 8 to 10 as subclinically expressed anxiety and/or depression, and above 10 points-clinically expressed anxiety and/or depression.

In the operating room intravenous (i.v.) peripheral canulla Vasofix Certo (B. Braun, Germany) with a diameter of 18 or 20 Gauge is inserted before the start of regional anesthesia for infusion therapy. Before spinal anesthesia an anesthesiologist inject 0.9% saline infusion (Grotex, Russia) of 6-8 ml/kg.

Following this procedure, the investigators perform a puncture of the subarachnoid space with a 27 Gauge Pencil Point needle (Bbraun, Germany) under aseptic conditions under local anesthesia with lidocaine (Pharmasyntez, Russia) at the L2-L4 level. The criterion for verifying the subarachnoid space is the appearance of liquor in the needle pavilion. After performing the aspiration test, 10-15 mg of an isobaric solution of moxicaine (Novosibhimfarm, Russia) is injected. To evaluate the sensory block, the investigators use the tactile sensitivity loss test ('pinprick' test), and the motor block-the Bromage test.

0.9% saline (20 - 25 ml/kg) is administered to patients in the all groups. Propofol (1 group (Propofol Kabi, Registration number from the State Register of Medicines - 000875)) or dexmedetomidine (2 group (Dexmedetomidine, Registration number from the State Register of Medicines - 005916) are used for sedation. Intravenous infusion of propofol or dexmedetomidine is performed with a BBraun Space (B. Braun Melsungen AG, Registration certificate for a medical device RZN 2013/905). Target control infusion (TCI, Shnider model) is applied for the dosing of propofol concentration. At the beginning of sedation, the level of the target propofol concentration is 1.5 - 2 mcg ml-1, during operation - 2.5 mcg ml-1. Intravenous infusion of dexmedetomidine starts with a dose of 1 mcg/kg for 10 minutes, with maintaining dose from 0.6 to 0.7 mcg/kg/min follows by titration from 0.2 to 2 mcg/kg/h depending on the level of sedation. Propofol or dexmedetomidine infusion terminates 10 minutes before the end of the operation. 0.9% saline (20 - 25 ml/kg) is administered to patients in the control group (3 group). Sedation is not performed in control group.

The Richmond agitation and sedation Scale (RASS) and bispectral index monitor A-2000XP (BIS, Aspect Medical Systems, Inc. (USA), Registration certificate for a medical device RZN 2005/498) are used to assess the depth of sedation. RASS values '-2' - '-3' (short-term eyes opening for less than 10 seconds or voluntary movements without eye contact in response to a call) correspond to light-moderate sedation, '-4' (eyes opening or voluntary movements in response to physical stimulation) - deep sedation. BIS values 70 - 90 correspond to light - moderate sedation, 60 - 70 - deep sedation.

To ensure patient safety, the investigators use the basic monitoring standard: noninvasive arterial pressure (NAP), heart rate (HR), electrocardiogram (ECG), SpO2, capnography (Philips Monitor IntelliVue MP40 (Medizin Systeme Boblingen GmbH, Germany, Registration certificate for a medical device RZN 2014/2009)).

Memory testing is conducted in three stages. Stage 1 - immediately prior to sedation, stage 2 - 5-10 minutes after the start of sedation (RASS '-1' - '-2', BIS 70 - 90), stage 3 - 10 minutes after sedation is finished and consciousness is restored (RASS '0', BIS 95 - 100). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The experimental words are different at each stage. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. To assess recall, the patients remember all the words listened before, during and after anesthesia. To test recognition, patients use to mark the words learned during surgery in the list of words, which consists of 15 experimental and 10 control. The number of words in recall and recognition testing is recorded by researcher.

Statistical analysis is perfomed in MS Excel and Jamovi 2.0.0 programs. The Shapiro-Wilk and Kolmogorov-Smirnov tests are used to determine the normality of the distribution. The analysis of the categorical variables is evaluated using the criterion χ2. For inter-group comparison of quantitative variables, one-way analysis of variance (one-way ANOVA) followed by post-hoc Bonferroni test are used. Repeated measures analysis of variance (RM-ANOVA) followed by post hoc tests for multiple comparisons, which are Bonferroni-adjusted, are performed to compare data within groups. Statistical significance level is set at P \< 0.05.

02

Conditions studied

  • Memory Impairment
  • Amnesia
  • Recall
  • Recognition

Browse trials for

Keywords

  • sedation
  • Memory consolidation
  • Propofol
  • Dexmedetomidine
03

In context

Amnesia Reclassified

22 studies on the registry are indexed under Amnesia; 2 are open to participants now.

This study's enrollment of 81 is above the median of 62 across 19 interventional studies indexed under Amnesia.

Browse Amnesia studies →

Lead sponsor

I.M. Sechenov First Moscow State Medical University is the lead sponsor of 137 studies on the registry; 28 are open to participants now.

Compared within Amnesia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Memory Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Age ≥ 18 and ≤70 years
  • Elective trauma surgery (arthroscopy, reconstructive foot surgery) under regional anesthesia (spinal anesthesia) with propofol, dexmedetomidine or without sedation
  • test ≥ 26
  • Patients with (ASA) I-II

Non-inclusion criteria:

  • Not written informed consent to participate in the research and/or perform regional blockade
  • Age˂18 and ˃70 years
  • Allergy to propofol, dexmedetomidine, lidocaine, bupivacaine
  • Pregnancy
  • Epilepsy anamnesis
  • II-III degree atrioventricular block
  • Montreal cognitive assessment test ˂ 26
  • Patients with American Society of Anesthesiologists (ASA) ˃ II
  • Emergency operation
  • The presence of psychiatric disorders
  • Сancer patients with a of less than two years
  • Taking anticoagulants, psychotropic drugs

Exclusion criteria

Exclusion Criteria:

  • Patient refuse from further participation
  • Ineffective spinal anesthesia
  • Allergy on anesthesia drugs during perioperative period
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    propofol group

    patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia with propofol sedation

    Drug: Influence of propofol sedation on memory consolidation and 'working memory'

  • Experimental
    dexmedetomidine group

    patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia with dexmedetomidine sedation

    Drug: Influence of dexmedetomidine sedation on memory consolidation and 'working memory'

  • Placebo comparator
    control group

    patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia without sedation

    Drug: Influence of spinal anesthesia on memory consolidation and 'working memory'

Interventions

  • DrugInfluence of propofol sedation on memory consolidation and 'working memory'

    Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to propofol sedation (stage 1), 5-10 minutes after the start of propofol sedation (stage 2), 10 minutes after propofol sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.

  • DrugInfluence of dexmedetomidine sedation on memory consolidation and 'working memory'

    Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to dexmedetomidine sedation (stage 1), 5-10 minutes after the start of dexmedetomidine sedation (stage 2), 10 minutes after dexmedetomidine sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.

  • DrugInfluence of spinal anesthesia on memory consolidation and 'working memory'

    Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.

06

What researchers measure

Primary outcomes

  1. memory consolidation impairment with propofol sedation

    Memorizing emotionally neutral words before, during and after propofol sedation. Evaluation of recall and recognition of words 24 hours after anesthesia.

    Time frame: 24 hours after the end of anesthesia

  2. memory consolidation impairment with dexmedetomidine sedation

    : Memorizing emotionally neutral words before, during and after dexmedetomidine sedation. Evaluation of recall and recognition of words 24 hours after anesthesia.

    Time frame: 24 hours after the end of anesthesia

  3. memory consolidation impairment without sedation

    Memorizing emotionally neutral words before, during and after operation. Evaluation of recall and recognition of words 24 hours after anesthesia.

    Time frame: 24 hours after the end of anesthesia

Secondary outcomes

  1. 'working memory' impairment with propofol sedation

    Memorizing emotionally neutral words during propofol sedation (stage 2). Evaluation of remembering and reproducing of words five minutes after learning.

    Time frame: 5 minutes after memorizing emotionally neutral words during propofol sedation

  2. 'working memory' impairment with dexmedetomidine sedation

    Memorizing emotionally neutral words during dexmedetomidine sedation (stage 2). Evaluation of remembering and reproducing of words five minutes after learning.

    Time frame: 5 minutes after memorizing emotionally neutral words during dexmedetomidine sedation

  3. 'working memory' impairment without sedation

    Memorizing emotionally neutral words during operation (stage 2). Evaluation of remembering and reproducing of words five minutes after learning.

    Time frame: 5 minutes after memorizing emotionally neutral words during operation

07

Study locations

1 site
  • City Clinical Hospital № 31 of the Department of Health of Moscow
    Moscow, Russian Federation
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The data will become available 31.10.2021

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Jan 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2021
First posted
Sep 16, 2021
StartActual
May 11, 2021
Primary completionActual
Jan 13, 2022
CompletionActual
Jan 13, 2022
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05045170
Responsible party
Sponsor
First posted
Sep 16, 2021
Start date
May 11, 2021
Primary completion
Jan 13, 2022
Completion
Jan 13, 2022
Last update
Feb 9, 2022

Study contacts

Vyacheslav Churakov, PgS
principal investigator · I.M. Sechenov First Moscow State Medical University (Sechenov University)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion